composition comprising a modified antigen, a method of immunizing using the composition, a vaccine comprising the composition and a method of treating autoimmune disease using the composition (Class 424, subclass 184). Claims 17-19 are drawn to a composition comprising antigen activated dendritic cells and a method of treating autoimmune disease using the activated cell composition (Class 424, subclass 93.1).

Applicants' elect to prosecute in this application the subject matter of claims 1-13 and 22-23 drawn to a method of producing a population of dendritic cell precursors prepared by the method classified on Class 435, subclass 240.2. Applicants however traverse the restriction requirement for the reasons discussed below.

The present invention relates to a method of producing a population of dendritic cell precursors, dendritic cells and antigens produced by this method and therapeutic applications thereof. The modified antigen of claims 14-16 (Group II) is a product of exposing the antigen to dendritic cells prepared by the method of claim 1 (Group I). The antigen activated dendritic cells of claim 17 (Group III) to be used in the therapeutic applications claimed in Claim 19 are also prepared by the method of claim 1, which is the subject matter of Group 1. Therefore applicants believe it would not be unduly burdensome for the Examiner to perform art searches directed to Groups I-III simultaneously. Particularly since Groups II and III are both classified in Class 424. This response is made with traverse and

without prejudice to a divisional application directed to the subject matter of claims 14-16 and 18 (Group II) and claims 17 and 19 (Group III).

<u>AUTHORIZATION</u>

No additional fee is believed to be necessary.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Response, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2016-4000US3.

If any questions or issues remain or if the Examiner has any comments or suggestions for expediting allowance of this application, he is urged to contact the undersigned at the telephone number below.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: July 6, 1995

By:

Carol M. Gruppi

Req. No. 37,341

Mailing Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, New York 10154 (212) 758-4800 (212) 751-6849 (Telecopier)